Should the blood pressure or the blood vessel be the target of therapy?

References

• Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung; and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Freis ED. Hemodynamics of hypertension. Physiol. Rev.40, 27–54 (1960).
   PubMed Web of Science ®Google Scholar
• Cohn JN. Is it the blood pressure or the blood vessel? J. Amer. Soc. Hypertens.1(1), 5–16 (2007).
   Google Scholar
• Folkow B. Myogenic mechanism in the control of systemic resistance. Introduction and historical background. J. Hypertension7, 51–54 (1989).
   Google Scholar
• Panza JA, Casino PR, Kilcoyne CM et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation87, 1468–1474 (1993).
   PubMed Web of Science ®Google Scholar
• McVeigh GE, Burns DE, Finkelstein SM et al. Reduced vascular compliance as a marker for essential hypertension. Am. J. Hypertension4, 245–251 (1991).
   PubMedGoogle Scholar
• Mulvaney MJ. Remodeling of resistance vessel structure in essential hypertension. Curr. Opin. Nephrol. Hypertens.2, 77–81 (1993).
   Google Scholar
• O’Leary DH, Polak JF, Kronmal RA et al. for the Cardiovascular Health Study Collaborative Research Group. Carotid–artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med.340, 14–22 (1999).
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension37, 1236–1241 (2001).
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Pauca AL. Augmentation of the aortic and central arterial pressure waveform. Blood Press Monit.9, 179–185 (2004).
   Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet362, 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Staessen JA, Angeli F et al.; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet374(9689), 525–533 (2009); erratum in: Lancet374(9693), 880 (2009).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter N et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al.; for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Gilani M, Kaiser DR, Bratteli CW et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J. Amer. Soc. Hypertens.1(1), 45–55 (2007).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Wilson DJ, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens.22(2), 137–144 (2009).
   PubMed Web of Science ®Google Scholar
• Peralta CA, Adeney KL, Shlipak MG et al. Structural and functional vascular alterations and incident hypertension in normotensive adults. The Multi-Ethnic Study of Atherosclerosis. Am. J. Epidemiology171(1), 63–71 (2010).
   PubMedGoogle Scholar
• Coll B, Feinstein SB. Carotid intima–media thickness measurements: techniques and clinical relevance. Curr. Atheroscler. Rep.10, 444–450 (2008).
   PubMed Web of Science ®Google Scholar
• Detrano R, Guerci AD, Carr J et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N. Engl. J. Med.358, 1336–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Segura J. Predictors of the evolution of microalbuminuria. Hypertension48, 832–833 (2006).
   Google Scholar
• Duprez DA, Cohn JN. Time to foster a rational approach to preventing cardiovascular morbid events. J. Am. Coll. Cardiol.52, 327–329 (2008).
   Google Scholar